Manufacturer‐documented infrared interference from SSRIs: A confound in breast milk fat and pharmacokinetic studies re: (1) Monfort A., et al. Br J Clin Pharmacol. 2024;90(11):2849–2860. (2) Weisskopf E, et al. Br J Clin Pharmacol. 2020;86:1642–1653

Documenti analoghi

• Letter to the editor of the Brit J Clin Pharmacol on Hartjes et al. 2025 https://doi.org/10.1002/bcp.70176
  di: Rafael Henry‐Venson
  Pubblicazione: (2025)
• Letter to the editor of the Brit J Clin Pharmacol on Heuberger et al. 2025 https://doi.org/10.1002/bcp.70090
  di: Markus Hinder, et al.
  Pubblicazione: (2025)
• Corrigendum to "Degradation of NLRP3 by selective ROCK2 inhibitor alleviates acute lung injury" [Eur. J. Pharmacol. 1004 (2025) 178009].
  di: Zhan, Shuai, et al.
  Pubblicazione: (2025)
• Letter regarding Pini, A., Nardini, P., Zizi, V., Molino, M., Calvani, M., Carrozzo, F., … Filippi, L. (2026). β 3 ‐adrenoceptor agonism exerts lung protection in a rat model of bronchopulmonary dysplasia. Br J Pharmacol, in press
  di: Torsten Christ, et al.
  Pubblicazione: (2026)
• Validación del ClinESSDAI para Argentina
  di: Julieta Silvana Morbiducci
  Pubblicazione: (2023)